A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer

被引：268

作者：

Ramanathan, Ramesh K. ^{[1
,2
]}

Belani, Chandra P. ^{[2
]}

Singh, Deepti A. ^{[3
]}

Tanaka, Michael ^{[4
]}

Lenz, Heinz-Josef ^{[5
]}

Yen, Yun ^{[6
]}

Kindler, Hedy L. ^{[3
]}

Iqbal, Syma ^{[5
]}

Longmate, Jeff ^{[6
]}

Mack, Philip C. ^{[4
]}

Lurje, Georg ^{[5
]}

Gandour-Edwards, Regina ^{[4
]}

Dancey, Janet ^{[7
]}

Gandara, David R. ^{[4
]}

机构：

[1] Scottsdale Clin Res Inst, Scottsdale, AZ 85258 USA

[2] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA

[3] Univ Chicago, Chicago, IL 60637 USA

[4] Univ Calif, Davis Canc Ctr, Sacramento, CA USA

[5] Univ So Calif, Norris Canc Ctr, Los Angeles, CA USA

[6] City Hope Natl Canc Ctr, Duarte, CA USA

[7] NCI, Canc Therapy Evaluat Program, Invest Drug Branch, Bethesda, MD 20892 USA

来源：

CANCER CHEMOTHERAPY AND PHARMACOLOGY | 2009年 / 64卷 / 04期

关键词：

Lapatinib; Phase II study; Hepatocellular cancer; Biliary tree cancer; CLINICAL-TRIALS; BREAST-CANCER; INTRON; CARCINOMA; ERLOTINIB; CHOLANGIOCARCINOMA; EXPRESSION; INHIBITOR; MUTATIONS; CELLS;

D O I：

10.1007/s00280-009-0927-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

To evaluate the response to lapatinib, an inhibitor of epidermal growth factor receptors 1 and 2, in patients with advanced bilary tree cancer (BTC) and hepatocellular cancer (HCC). Lapatinib was dosed at 1,500 mg/day orally continuously. Fifty-seven patients were accrued (BTC 17, HCC 40). Therapy was well tolerated. The response in BTC was 0% and in HCC was 5%. The progression free survival (PFS) for BTC and HCC patients was 1.8 (95% CI: 1.7-5.2) months and 2.3 (95% CI: 1.7-5.6) months. The median survival for BTC and HCC patients was 5.2 (95% CI 3.3-a) months and 6.2 (95% CI: 5.1-a) months. EGFR genotyping indicated HCC patients with < 20 repeats have the lowest PFS. The occurrence of any skin rash significantly prolonged PFS and survival. Lapatinib was well-tolerated. There was evidence of activity in HCC, but therapy with lapatinib did not meet the predefined efficacy rate.

引用

页码：777 / 783

页数：7

共 30 条

[1] Treatment options for hepatobiliary and pancreatic cancer [J].

Alberts, Steven R. ;

Gores, Gregory J. ;

Kim, George P. ;

Roberts, Lewis R. ;

Kendrick, Michael L. ;

Rosen, Charles B. ;

Chari, Suresh T. ;

Martenson, James A. .

MAYO CLINIC PROCEEDINGS, 2007, 82 (05) :628-637

[2]

BARTLETT D, 2008, CANC PRINCIPLES PRAC

[3] A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma [J].

Bekaii-Saab, Tanios ;

Williams, Nita ;

Plass, Christoph ;

Calero, Miguel Villalona ;

Eng, Charis .

BMC CANCER, 2006, 6 (1)

[4] New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system [J].

Berasain, Carmen ;

Castillo, Josefa ;

Prieto, Jesus ;

Avila, Matias A. .

LIVER INTERNATIONAL, 2007, 27 (02) :174-185

[5]

Buerger H, 2000, CANCER RES, V60, P854

[6] Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis [J].

El-Serag, Hashem B. ;

Rudolph, Lenhard .

GASTROENTEROLOGY, 2007, 132 (07) :2557-2576

[7] Origin and prognostic value of circulating KRAS mutations in lung cancer patients [J].

Gautschi, O. ;

Huegli, B. ;

Ziegler, A. ;

Gugger, M. ;

Heighway, J. ;

Ratschiller, D. ;

Mack, P. C. ;

Gumerlock, P. H. ;

Kung, H. J. ;

Stahel, R. A. ;

Gandara, D. R. ;

Betticher, D. C. .

CANCER LETTERS, 2007, 254 (02) :265-273

[8] Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1 [J].

Gebhardt, F ;

Zänker, KS ;

Brandt, B .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (19) :13176-13180

[9] Lapatinib plus capecitabine for HER2-positive advanced breast cancer [J].

Geyer, Charles E. ;

Forster, John ;

Lindquist, Deborah ;

Chan, Stephen ;

Romieu, C. Gilles ;

Pienkowski, Tadeusz ;

Jagiello-Gruszfeld, Agnieszka ;

Crown, John ;

Chan, Arlene ;

Kaufman, Bella ;

Skarlos, Dimosthenis ;

Campone, Mario ;

Davidson, Neville ;

Berger, Mark ;

Oliva, Cristina ;

Rubin, Stephen D. ;

Stein, Steven ;

Cameron, David .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (26) :2733-2743

[10] Sorafenib in advanced hepatocellular carcinoma [J].

Llovet, Josep M. ;

Ricci, Sergio ;

Mazzaferro, Vincenzo ;

Hilgard, Philip ;

Gane, Edward ;

Blanc, Jean-Frederic ;

Cosme de Oliveira, Andre ;

Santoro, Armando ;

Raoul, Jean-Luc ;

Forner, Alejandro ;

Schwartz, Myron ;

Porta, Camillo ;

Zeuzem, Stefan ;

Bolondi, Luigi ;

Greten, Tim F. ;

Galle, Peter R. ;

Seitz, Jean-Francois ;

Borbath, Ivan ;

Haussinger, Dieter ;

Giannaris, Tom ;

Shan, Minghua ;

Moscovici, Marius ;

Voliotis, Dimitris ;

Bruix, Jordi .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (04) :378-390

← 1 2 3 →